Health Care Equipment
19 companies under coverage.
Health Care Equipment
Zimmer Biomet Holdings Inc (ZBH)
HOLD. 12-month probability-weighted target $90 (-11% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.
Stryker Corporation (SYK)
HOLD. 12-month probability-weighted target $314 (-4% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.
STERIS plc (STE)
SELL. 12-month probability-weighted target $210 (-12% vs spot). P/E Multiple explains 60% of Monte Carlo outcome variance.
Revvity Inc. (RVTY)
SELL. 12-month probability-weighted target $108 (-12% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.
ResMed Inc (RMD)
SELL. 12-month probability-weighted target $201 (-13% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Insulet Corporation (PODD)
HOLD. 12-month probability-weighted target $151 (+4% vs spot). P/E Multiple explains 52% of Monte Carlo outcome variance.
Medtronic PLC (MDT)
HOLD. 12-month probability-weighted target $86 (-7% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.
LivaNova PLC (LIVN)
HOLD. 12-month probability-weighted target $79 (+1% vs spot). P/E Multiple explains 55% of Monte Carlo outcome variance.
Intuitive Surgical Inc (ISRG)
HOLD. 12-month probability-weighted target $404 (+8% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.
IDEXX Laboratories Inc (IDXX)
HOLD. 12-month probability-weighted target $542 (-3% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.
Globus Medical (GMED)
SELL. 12-month probability-weighted target $76 (-9% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.
GE HealthCare Technologies Inc. (GEHC)
SELL. 12-month probability-weighted target $63 (-15% vs spot). Gross Margin explains 62% of Monte Carlo outcome variance.
Edwards Lifesciences Corp (EW)
HOLD. 12-month probability-weighted target $88 (-3% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.
DexCom Inc (DXCM)
SELL. 12-month probability-weighted target $65 (-28% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.
Boston Scientific Corp (BSX)
SELL. 12-month probability-weighted target $44 (-11% vs spot). P/E Multiple explains 71% of Monte Carlo outcome variance.
Bruker Corporation (BRKR)
HOLD. 12-month probability-weighted target $55 (-3% vs spot). P/E Multiple explains 57% of Monte Carlo outcome variance.
Becton Dickinson and Company (BDX)
SELL. 12-month probability-weighted target $147 (-23% vs spot). P/E Multiple explains 56% of Monte Carlo outcome variance.
Baxter International Inc (BAX)
SELL. 12-month probability-weighted target $20 (-23% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.
Abbott Laboratories (ABT)
SELL. 12-month probability-weighted target $93 (-20% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.